Neurometrix Falls After Report of Fraud Investigation

Neurometrix Inc. shares fell 8 percent after the Boston Globe reported that the company, which makes devices that diagnose carpal-tunnel syndrome, is being investigated for possible health-care fraud.

Shares of the Waltham, Massachusetts-based company fell 84 cents to $10.18 as of 4 p.m. New York time in Nasdaq stock market composite trading.

The Boston Globe reported federal prosecutors will investigate whether the company was complicit in fraud against the government and kickbacks to doctors who use its NC-Stat system, which is used to diagnose nerve-related medical problems.

Kara Canoni, a Neurometrix spokeswoman, didn't return calls for comment from Bloomberg News. Neurometrix executives told the Globe yesterday they had no information about a grand jury meeting.

To contact the reporter on this story: Todd Zeranski in New York at tzeranski@bloomberg.net

To contact the editor responsible for this story: JoAnne Norton at jnorton@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.